source
- GSK to spend up to $1.3 billion on Hutchmed's dual-target cancer therapyGSK announced a deal to acquire the majority rights to Hutchmed's experimental therapy HMPL-A830. The agreement includes an upfront payment of $110 million and potential milestone and royalty payme…
- Seattle researchers unveil $95 million AI biology initiative to map nature’s design rulesSeattle scientists have announced a new $95 million effort that uses artificial intelligence to decode the design principles of biological molecules. The project, led by Nobel laureate David Baker,…